meta_review,paper,Intervention,Age,Outcome,followup_rank,Raters,Class,measure,value,CI_95,CI_lower,CI_upper,p_value,PI_95,n_studies,total_n,egger_p,ESB_p,indirectness,report,rob,es,ci_lo,ci_up,Factor
93,Ang (2023),Acupuncture,Children/Adolescents (6-17yo),Generalized anxiety,Endpoint (~12wk),Parent-rated,Low,G,0.039,"[-0.258, 0.336]",-0.258,0.336,7.97e-01,"[-1.888, 1.966]",2,171,NaN,6.10e-01,no,100,100,0.039,-0.258,0.336,Ang (2023)_Acupuncture_Generalized anxiety_Parent-rated_At study endpoint (closest to 12 weeks)
93,Ang (2023),Acupuncture,Children/Adolescents (6-17yo),Learning disorder symptoms,Endpoint (~12wk),Parent-rated,Very low,G,0.625,"[0.321, 0.93]",0.321,0.93,5.72e-05,"[-1.349, 2.6]",2,171,NaN,1.91e-01,no,100,100,0.625,0.321,0.93,Ang (2023)_Acupuncture_Learning disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)
93,Ang (2023),Acupuncture,Children/Adolescents (6-17yo),Conduct disorder symptoms (CD),Endpoint (~12wk),Parent-rated,Very low,G,0.662,"[0.356, 0.968]",0.356,0.968,2.17e-05,"[-1.319, 2.643]",2,171,NaN,2.69e-01,no,100,100,0.662,0.356,0.968,Ang (2023)_Acupuncture_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)
93,Ang (2023),Acupuncture,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Endpoint (~12wk),Parent-rated,Very low,G,0.793,"[0.484, 1.101]",0.484,1.101,4.96e-07,"[-1.21, 2.795]",2,171,NaN,3.67e-01,no,100,100,0.793,0.484,1.101,Ang (2023)_Acupuncture_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Alpha-2 agonists (guanfacine / clonidine),Children/Adolescents (6-17yo),Core ADHD symptoms [Clinician-rated],Endpoint (~12wk),Clinician-rated,High,G,0.635,"[0.479, 0.79]",0.479,0.79,1.19e-15,"[0.26, 1.01]",8,1497,3.62e-01,2.31e-01,no,100,86.8603457270275,0.635,0.479,0.79,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Alpha-2 agonists (guanfacine / clonidine),Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Low,RR,1.366,"[1.047, 1.781]",1.047,1.781,2.13e-02,"[0.683, 2.73]",11,1456,5.81e-01,6.05e-01,no,100,84.3438776794575,0.311886761148598,0.0459289318883997,0.577175004307525,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
8992,Fahrat (2024),Alpha-2 agonists (guanfacine / clonidine),Children/Adolescents (6-17yo),Tics/Tourette disorder symptoms,Endpoint (~12wk),N/A,Low,G,0.771,"[0.524, 1.018]",0.524,1.018,8.84e-10,"[0.371, 1.171]",4,297,5.47e-01,1.64e-01,no,100,100,0.771,0.524,1.018,Fahrat (2024)_Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Alpha-2 agonists (guanfacine / clonidine),Children/Adolescents (6-17yo),Tolerability,Endpoint (~12wk),,Very low,RR,0.281,"[0.125, 0.634]",0.125,0.634,2.21e-03,"[0.056, 1.415]",8,1287,4.30e-01,2.51e-03,no,100,86.6889648171869,-1.26940060964839,-2.07944154167984,-0.455706324544911,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
3090,Ruggiero (2014),Alpha-2 agonists (guanfacine / clonidine),Children/Adolescents (6-17yo),AE (sleep problems),Endpoint (~12wk),,Very low,RR,0.3,"[0.169, 0.532]",0.169,0.532,3.76e-05,"[0.051, 1.755]",6,1704,6.08e-02,3.31e-04,no,79.627556838023,79.627556838023,-1.20397280432594,-1.77785656405906,-0.631111789640493,Ruggiero (2014)_Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)
2902,Radonjic (2023),Alpha-2 agonists (guanfacine / clonidine),Adults (>=18yo),Core ADHD symptoms [Mixed],Endpoint (~12wk),Mixed,Very low,G,0.66,"[0.382, 0.939]",0.382,0.939,3.24e-06,"[-1.142, 2.463]",2,235,NaN,7.86e-01,no,17.5121083619884,17.5121083619884,0.66,0.382,0.939,Radonjic (2023)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)
2877,Punja (2016),Amphetamines,Children/Adolescents (6-17yo),AE (decreased appetite),Endpoint (~12wk),,Low,RR,0.185,"[0.104, 0.329]",0.104,0.329,1.02e-08,"[0.037, 0.927]",11,2467,6.26e-03,2.73e-01,no,70.8011349391913,70.8011349391913,-1.68739945390381,-2.26336437984076,-1.11169752821676,Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)
2877,Punja (2016),Amphetamines,Children/Adolescents (6-17yo),AE (sleep problems),Endpoint (~12wk),,Low,RR,0.281,"[0.174, 0.456]",0.174,0.456,2.52e-07,"[0.088, 0.898]",10,2429,9.06e-02,4.69e-01,no,67.3035477565818,67.3035477565818,-1.26940060964839,-1.74869997976761,-0.785262469467751,Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Amphetamines,Children/Adolescents (6-17yo),Tolerability,Endpoint (~12wk),,Moderate,RR,0.463,"[0.223, 0.959]",0.223,0.959,3.83e-02,"[0.174, 1.228]",7,1343,1.84e-01,4.34e-01,no,100,100,-0.770028224895903,-1.50058350752202,-0.0418642040986989,Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Amphetamines,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Moderate,RR,1.227,"[0.858, 1.756]",0.858,1.756,2.63e-01,"[0.486, 3.1]",7,1343,1.12e-01,4.74e-01,no,100,100,0.204572165728775,-0.153151179494175,0.563038495212925,Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
2877,Punja (2016),Amphetamines,Children/Adolescents (6-17yo),Academic/job performance,Endpoint (~12wk),,Moderate,G,0.551,"[0.374, 0.728]",0.374,0.728,1.02e-09,"[0.149, 0.952]",8,826,3.52e-02,9.07e-01,no,100,100,0.551,0.374,0.728,Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Amphetamines,Children/Adolescents (6-17yo),Core ADHD symptoms [Clinician-rated],Endpoint (~12wk),Clinician-rated,Moderate,G,1.024,"[0.672, 1.376]",0.672,1.376,1.17e-08,"[-0.078, 2.126]",5,876,5.11e-01,3.55e-01,no,100,100,1.024,0.672,1.376,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)
2877,Punja (2016),Amphetamines,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Endpoint (~12wk),Parent-rated,Low,G,0.568,"[0.28, 0.855]",0.28,0.855,1.07e-04,"[-0.288, 1.423]",7,1247,6.63e-01,5.71e-01,no,82.6508569833238,82.6508569833238,0.568,0.28,0.855,Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)
8888,Bellatto - children (2024),Amphetamines,Children/Adolescents (6-17yo),Quality of life,Endpoint (~12wk),Self-rated,Very low,G,0.475,"[-0.523, 1.474]",-0.523,1.474,3.51e-01,"[-10.598, 11.548]",2,521,NaN,6.16e-01,no,100,100,0.475,-0.523,1.474,Bellatto - children (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)
2877,Punja (2016),Amphetamines,Children/Adolescents (6-17yo),Core ADHD symptoms [Teacher-rated],Endpoint (~12wk),Teacher-rated,Very low,G,0.553,"[0.274, 0.833]",0.274,0.833,1.04e-04,"[-0.141, 1.248]",5,745,4.38e-01,2.25e-01,no,100,100,0.553,0.274,0.833,Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)
2877,Punja (2016),Amphetamines,Children/Adolescents (6-17yo),CGI,Endpoint (~12wk),N/A,Very low,G,0.873,"[0.012, 1.733]",0.012,1.733,4.69e-02,"[-7.752, 9.497]",2,86,NaN,5.90e-01,no,100,100,0.873,0.012,1.733,Punja (2016)_Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)
1110,Faraone (2002),Amphetamines,Children/Adolescents (6-17yo),Disruptive behaviors,Endpoint (~12wk),N/A,Very low,G,1.049,"[0.645, 1.453]",0.645,1.453,3.70e-07,"[-0.156, 2.254]",3,130,3.34e-01,9.24e-01,no,0,0,1.049,0.645,1.453,Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Amphetamines,Adults (>=18yo),Tolerability,Endpoint (~12wk),,High,RR,0.398,"[0.22, 0.718]",0.22,0.718,2.24e-03,"[0.203, 0.779]",11,1995,8.58e-01,9.17e-01,no,96.4312148914133,96.4312148914133,-0.921303273697699,-1.51412773262978,-0.331285709933913,Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Amphetamines,Adults (>=18yo),Acceptability,Endpoint (~12wk),,Moderate,RR,1.189,"[0.951, 1.485]",0.951,1.485,1.29e-01,"[0.747, 1.89]",10,1957,6.07e-01,6.42e-01,no,100,100,0.173112617708645,-0.0502412164367468,0.395414772254663,Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Amphetamines,Adults (>=18yo),Core ADHD symptoms [Self-rated],Endpoint (~12wk),Self-rated,Low,G,0.534,"[0.297, 0.77]",0.297,0.77,9.58e-06,"[0.15, 0.917]",4,300,5.04e-01,5.60e-01,no,100,100,0.534,0.297,0.77,Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Amphetamines,Adults (>=18yo),Core ADHD symptoms [Clinician-rated],Endpoint (~12wk),Clinician-rated,Low,G,0.631,"[0.395, 0.868]",0.395,0.868,1.71e-07,"[-0.113, 1.376]",9,1857,3.14e-01,3.76e-01,no,86.6190203861575,86.6190203861575,0.631,0.395,0.868,Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)
563,Castells (2018),Amphetamines,Adults (>=18yo),Depressive disorder symptoms,Endpoint (~12wk),Clinician-rated,Very low,G,-0.157,"[-0.523, 0.209]",-0.523,0.209,4.00e-01,"[-2.529, 2.215]",2,110,NaN,6.68e-01,no,100,100,-0.157,-0.523,0.209,Castells (2018)_Amphetamine_Depressive disorder symptoms_Clinician-rated_At study endpoint (closest to 12 weeks)
563,Castells (2018),Amphetamines,Adults (>=18yo),Generalized anxiety,Endpoint (~12wk),Clinician-rated,Very low,G,-0.13,"[-0.495, 0.236]",-0.495,0.236,4.88e-01,"[-2.502, 2.243]",2,110,NaN,6.52e-01,no,100,100,-0.13,-0.495,0.236,Castells (2018)_Amphetamine_Generalized anxiety_Clinician-rated_At study endpoint (closest to 12 weeks)
2027,Lenzi (2018),Amphetamines,Adults (>=18yo),Emotional dysregulation,Endpoint (~12wk),N/A,Very low,G,0.344,"[0.121, 0.567]",0.121,0.567,2.54e-03,"[-0.407, 1.095]",3,235,1.18e-01,9.93e-02,no,100,100,0.344,0.121,0.567,Lenzi (2018)_Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)
8888,Bellato - adults (2024),Amphetamines,Adults (>=18yo),Quality of life,Endpoint (~12wk),Self-rated,Very low,G,0.524,"[0.325, 0.723]",0.325,0.723,2.51e-07,"[-1.02, 2.067]",2,429,NaN,3.55e-01,no,100,100,0.524,0.325,0.723,Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)
1056,Elliott (2020),Amphetamines,Adults (>=18yo),Exec. functions (report),Endpoint (~12wk),N/A,Very low,G,0.655,"[0.507, 0.804]",0.507,0.804,5.79e-18,"[0.414, 0.897]",4,722,8.13e-01,3.86e-01,no,0,0,0.655,0.507,0.804,Elliott (2020)_Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)
563,Castells (2018),Amphetamines,Adults (>=18yo),CGI,Endpoint (~12wk),N/A,Very low,G,0.85,"[0.594, 1.105]",0.594,1.105,7.20e-11,"[0.201, 1.498]",3,341,6.59e-02,1.19e-01,no,100,100,0.85,0.594,1.105,Castells (2018)_Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Atomoxetine,Children/Adolescents (6-17yo),Tolerability,Endpoint (~12wk),,High,RR,0.542,"[0.273, 1.077]",0.273,1.077,8.03e-02,"[0.251, 1.171]",12,1799,4.56e-01,8.33e-01,no,100,100,-0.612489277542491,-1.29828348379718,0.0741793981742515,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Atomoxetine,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,High,RR,0.999,"[0.767, 1.3]",0.767,1.3,9.93e-01,"[0.612, 1.63]",13,1831,1.72e-01,7.73e-01,no,100,100,-0.00100050033358353,-0.265268477614881,0.262364264467491,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Atomoxetine,Children/Adolescents (6-17yo),Core ADHD symptoms [Clinician-rated],Endpoint (~12wk),Clinician-rated,Moderate,G,0.527,"[0.415, 0.64]",0.415,0.64,3.82e-20,"[0.211, 0.844]",17,2467,6.76e-02,3.67e-01,no,100,100,0.527,0.415,0.64,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)
474,Bryant (2021),Atomoxetine,Children/Adolescents (6-17yo),Generalized anxiety,Endpoint (~12wk),N/A,Low,G,0.17,"[-0.128, 0.468]",-0.128,0.468,2.63e-01,"[-0.931, 1.272]",3,498,8.30e-01,4.11e-01,no,100,100,0.17,-0.128,0.468,Bryant (2021)_Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)
8888,Bellatto - children (2024),Atomoxetine,Children/Adolescents (6-17yo),Quality of life,Endpoint (~12wk),,Moderate,G,0.334,"[0.193, 0.476]",0.193,0.476,3.39e-06,"[0.066, 0.602]",6,1179,8.25e-01,9.29e-01,no,100,83.1353741817394,0.334,0.193,0.476,Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)
474,Bryant (2021),Atomoxetine,Children/Adolescents (6-17yo),Depressive disorder symptoms,Endpoint (~12wk),N/A,Very low,G,0.152,"[-0.043, 0.346]",-0.043,0.346,1.26e-01,"[-0.348, 0.651]",4,774,8.89e-01,4.62e-01,no,100,100,0.152,-0.043,0.346,Bryant (2021)_Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Atomoxetine,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Endpoint (~12wk),Parent-rated,Very low,G,0.403,"[0.032, 0.773]",0.032,0.773,3.33e-02,"[-0.852, 1.657]",8,1218,6.62e-01,7.16e-05,no,100,100,0.403,0.032,0.773,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Atomoxetine,Children/Adolescents (6-17yo),Core ADHD symptoms [Teacher-rated],Endpoint (~12wk),Teacher-rated,Very low,G,0.447,"[-0.058, 0.952]",-0.058,0.952,8.24e-02,"[-3.773, 4.667]",2,119,NaN,3.48e-01,no,100,100,0.447,-0.058,0.952,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Atomoxetine,Adults (>=18yo),Tolerability,Endpoint (~12wk),,High,RR,0.448,"[0.347, 0.579]",0.347,0.579,8.47e-10,"[0.338, 0.595]",14,3292,7.51e-01,6.01e-01,no,100,100,-0.802962046567152,-1.05843049903528,-0.546452801409142,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
2027,Lenzi (2018),Atomoxetine,Adults (>=18yo),Emotional dysregulation,Endpoint (~12wk),N/A,High,G,0.244,"[0.143, 0.345]",0.143,0.345,2.06e-06,"[0.076, 0.412]",5,2373,7.76e-01,4.43e-01,no,100,100,0.244,0.143,0.345,Lenzi (2018)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Atomoxetine,Adults (>=18yo),Core ADHD symptoms [Self-rated],Endpoint (~12wk),Self-rated,High,G,0.368,"[0.265, 0.471]",0.265,0.471,2.31e-12,"[0.24, 0.496]",7,1734,7.38e-01,3.95e-01,no,100,100,0.368,0.265,0.471,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Atomoxetine,Adults (>=18yo),Acceptability,Endpoint (~12wk),,Moderate,RR,0.818,"[0.74, 0.904]",0.74,0.904,8.41e-05,"[0.667, 1.004]",14,3292,6.42e-01,5.75e-01,no,100,100,-0.20089294237939,-0.301105092783922,-0.100925918589961,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Atomoxetine,Adults (>=18yo),Quality of life,Endpoint (~12wk),N/A,Very low,G,-0.222,"[-0.376, -0.068]",-0.376,-0.068,4.69e-03,"[-1.219, 0.775]",2,651,NaN,5.17e-01,no,100,100,-0.222,-0.376,-0.068,Ostinelli (2025)_Atomoxetine_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Atomoxetine,Adults (>=18yo),Core ADHD symptoms [Clinician-rated],Follow-up (~26wk),Clinician-rated,Very low,G,0.33,"[0.075, 0.585]",0.075,0.585,1.12e-02,"[-0.599, 1.259]",3,1006,8.54e-01,5.88e-01,no,100,100,0.33,0.075,0.585,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)
999,Ostinelli (2025),Atomoxetine,Adults (>=18yo),Core ADHD symptoms [Self-rated],Follow-up (~26wk),Self-rated,Very low,G,0.354,"[0.215, 0.493]",0.215,0.493,6.51e-07,"[-0.588, 1.296]",2,872,NaN,3.61e-01,no,100,100,0.354,0.215,0.493,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)
1056,Elliott (2020),Atomoxetine,Adults (>=18yo),Exec. functions (report),Endpoint (~12wk),N/A,Very low,G,0.381,"[0.209, 0.554]",0.209,0.554,1.45e-05,"[-0.736, 1.499]",2,535,NaN,1.23e-01,no,0,0,0.381,0.209,0.554,Elliott (2020)_Atomoxetine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Atomoxetine,Adults (>=18yo),Core ADHD symptoms [Clinician-rated],Endpoint (~12wk),Clinician-rated,Very low,G,0.547,"[0.331, 0.763]",0.331,0.763,6.85e-07,"[-0.186, 1.28]",11,2537,2.60e-02,2.54e-01,no,100,100,0.547,0.331,0.763,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)
575,Catala-Lopez (2017),Bupropion,Children/Adolescents (6-17yo),Tolerability,Endpoint (~12wk),,Very low,RR,0.354,"[0.042, 2.953]",0.042,2.953,3.37e-01,"[0, 331981.587]",2,139,NaN,6.81e-01,no,0,0,-1.03845836584836,-3.17008566069877,1.08282160276179,Catala-Lopez (2017)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
575,Catala-Lopez (2017),Bupropion,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Very low,RR,0.683,"[0.185, 2.521]",0.185,2.521,5.67e-01,"[0, 3243.975]",2,139,NaN,6.39e-01,no,0,0,-0.381260419411347,-1.68739945390381,0.924655648205783,Catala-Lopez (2017)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
3442,Stuhec (2015),Bupropion,Children/Adolescents (6-17yo),Core ADHD symptoms [Mixed],Endpoint (~12wk),Mixed,Very low,G,0.314,"[-0.048, 0.676]",-0.048,0.676,8.95e-02,"[-2.034, 2.661]",2,124,NaN,7.74e-01,no,76.2923822738329,76.2923822738329,0.314,-0.048,0.676,Stuhec (2015)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)
3681,Verbeeck (2017),Bupropion,Adults (>=18yo),Depressive disorder symptoms,Endpoint (~12wk),N/A,Low,G,-0.16,"[-0.447, 0.127]",-0.447,0.127,2.73e-01,"[-2.021, 1.7]",2,184,NaN,6.96e-01,no,100,100,-0.16,-0.447,0.127,Verbeeck (2017)_Bupropion_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)
3681,Verbeeck (2017),Bupropion,Adults (>=18yo),Generalized anxiety,Endpoint (~12wk),N/A,Low,G,-0.106,"[-0.392, 0.181]",-0.392,0.181,4.71e-01,"[-1.965, 1.754]",2,184,NaN,6.54e-01,no,100,100,-0.106,-0.392,0.181,Verbeeck (2017)_Bupropion_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Bupropion,Adults (>=18yo),Acceptability,Endpoint (~12wk),,Very low,RR,0.972,"[0.212, 4.449]",0.212,4.449,9.70e-01,"[0, 620036.13]",2,99,NaN,6.91e-01,no,100,100,-0.028399474521698,-1.55116900431013,1.49267935182391,Ostinelli (2025)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Bupropion,Adults (>=18yo),Tolerability,Endpoint (~12wk),,Very low,RR,1.258,"[0.081, 19.591]",0.081,19.591,8.70e-01,"[0, 67568287.368]",2,99,NaN,6.02e-01,no,100,100,0.229523158278249,-2.5133061243097,2.9750702771059,Ostinelli (2025)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
757,Cortese - Adults (2018),Bupropion,Adults (>=18yo),Core ADHD symptoms [Clinician-rated],Endpoint (~12wk),Clinician-rated,Very low,G,0.386,"[0.079, 0.694]",0.079,0.694,1.38e-02,"[-1.606, 2.378]",2,202,NaN,4.59e-01,no,100,100,0.386,0.079,0.694,Cortese - Adults (2018)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Bupropion,Adults (>=18yo),Core ADHD symptoms [Self-rated],Endpoint (~12wk),Self-rated,Very low,G,0.798,"[0.25, 1.345]",0.25,1.345,4.28e-03,"[-2.75, 4.346]",2,64,NaN,6.28e-01,no,100,100,0.798,0.25,1.345,Ostinelli (2025)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)
575,Catala-Lopez (2017),Carnitine,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Very low,RR,1.242,"[0.762, 2.024]",0.762,2.024,3.84e-01,"[0.562, 2.745]",4,247,3.33e-02,6.93e-01,no,88.0585792247171,88.0585792247171,0.216722983511287,-0.271808723295491,0.705075751425219,Catala-Lopez (2017)_Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
8993,Maji (2024.0),Centafanadine,Adults (>=18yo),Core ADHD symptoms [Mixed],Endpoint (~12wk),Mixed,Very low,G,0.434,"[0.076, 0.792]",0.076,0.792,1.75e-02,"[-2.993, 3.861]",2,444,NaN,6.55e-02,no,100,100,0.434,0.076,0.792,Maji (2024.0)_Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)
962,Ding (2018),Cognitive Behavioral Therapy (CBT),Children/Adolescents (6-17yo),Core ADHD symptoms [Mixed],Endpoint (~12wk),Mixed,Very low,G,0.697,"[0.394, 1]",0.394,1,6.38e-06,"[0.033, 1.362]",3,167,5.90e-01,5.34e-02,no,100,100,0.697,0.394,1,Ding (2018)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Cognitive Behavioral Therapy (CBT),Adults (>=18yo),Core ADHD symptoms [Clinician-rated],Endpoint (~12wk),Clinician-rated,Moderate,G,0.528,"[0.286, 0.771]",0.286,0.771,1.98e-05,"[0.185, 0.872]",5,265,7.16e-01,2.67e-01,no,100,100,0.528,0.286,0.771,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Cognitive Behavioral Therapy (CBT),Adults (>=18yo),Acceptability,Endpoint (~12wk),,Low,RR,1.106,"[0.745, 1.642]",0.745,1.642,6.18e-01,"[0.493, 2.479]",10,867,7.04e-02,4.00e-02,no,100,100,0.100749903100143,-0.294371060602578,0.495915011030236,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Cognitive Behavioral Therapy (CBT),Adults (>=18yo),Tolerability,Endpoint (~12wk),,Very low,RR,1.071,"[0.114, 10.067]",0.114,10.067,9.52e-01,"[0.008, 146.536]",3,184,7.52e-01,6.14e-01,no,100,100,0.0685927914656117,-2.17155683058764,2.30926274774729,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Cognitive Behavioral Therapy (CBT),Adults (>=18yo),Quality of life,Endpoint (~12wk),N/A,Very low,G,0.259,"[-0.181, 0.7]",-0.181,0.7,2.48e-01,"[-2.596, 3.115]",2,77,NaN,7.08e-01,no,100,100,0.259,-0.181,0.7,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Cognitive Behavioral Therapy (CBT),Adults (>=18yo),Core ADHD symptoms [Clinician-rated],Follow-up (~26wk),Clinician-rated,Very low,G,0.31,"[-0.064, 0.684]",-0.064,0.684,1.04e-01,"[-2.115, 2.736]",2,109,NaN,7.67e-01,no,100,100,0.31,-0.064,0.684,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)
2154,Lopez (2018),Cognitive Behavioral Therapy (CBT),Adults (>=18yo),Generalized anxiety,Endpoint (~12wk),Self-rated,Very low,G,0.345,"[0.045, 0.644]",0.045,0.644,2.40e-02,"[-0.141, 0.831]",4,168,1.88e-01,4.25e-01,no,100,100,0.345,0.045,0.644,Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Cognitive Behavioral Therapy (CBT),Adults (>=18yo),Core ADHD symptoms [Self-rated],Endpoint (~12wk),Self-rated,Very low,G,0.366,"[0.153, 0.58]",0.153,0.58,7.73e-04,"[-0.132, 0.864]",9,607,3.11e-01,3.98e-01,no,86.2706038431898,86.2706038431898,0.366,0.153,0.58,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)
2154,Lopez (2018),Cognitive Behavioral Therapy (CBT),Adults (>=18yo),Depressive disorder symptoms,Endpoint (~12wk),Self-rated,Very low,G,0.452,"[0.137, 0.768]",0.137,0.768,4.90e-03,"[-0.151, 1.056]",5,187,3.41e-01,3.25e-01,no,100,100,0.452,0.137,0.768,Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Cognitive Behavioral Therapy (CBT),Adults (>=18yo),Core ADHD symptoms [Self-rated],Follow-up (~26wk),Self-rated,Very low,G,0.562,"[0.297, 0.827]",0.297,0.827,3.22e-05,"[-0.065, 1.189]",5,413,1.21e-01,2.15e-02,no,86.3566169778306,86.3566169778306,0.562,0.297,0.827,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)
999,Ostinelli (2025),Cognitive Behavioral Therapy (CBT),Adults (>=18yo),Core ADHD symptoms [Self-rated],Follow-up (~52wk),Self-rated,Very low,G,0.596,"[-0.095, 1.286]",-0.095,1.286,9.07e-02,"[-6.267, 7.458]",2,109,NaN,5.12e-01,no,54.191709116829,54.191709116829,0.596,-0.095,1.286,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)
2118,Liu (2022),Cognitive Behavioral Therapy (CBT),Adults (>=18yo),CGI,Endpoint (~12wk),Clinician-rated,Very low,G,1.145,"[0.311, 1.978]",0.311,1.978,7.12e-03,"[-1.606, 3.895]",5,260,3.70e-01,7.51e-01,no,100,61.3445578908854,1.145,0.311,1.978,Liu (2022)_Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)
3836,Westwood - Children (2024),Cognitive training,Children/Adolescents (6-17yo),Core ADHD symptoms [Teacher-rated],Endpoint (~12wk),Teacher-rated,Low,G,0.114,"[-0.044, 0.273]",-0.044,0.273,1.58e-01,"[-0.084, 0.312]",7,395,3.19e-01,7.78e-01,no,90.6269721951625,65.2065013131306,0.114,-0.044,0.273,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)
3836,Westwood - Children (2024),Cognitive training,Children/Adolescents (6-17yo),Exec. functions (tests),Endpoint (~12wk),,Low,G,0.199,"[0.059, 0.339]",0.059,0.339,5.27e-03,"[0.04, 0.358]",11,623,3.59e-01,6.41e-01,no,91.4055652109728,52.332518511318,0.199,0.059,0.339,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)
575,Catala-Lopez (2017),Cognitive training,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Very low,RR,0.609,"[0.366, 1.012]",0.366,1.012,5.57e-02,"[0.33, 1.124]",8,535,5.27e-01,8.25e-01,no,94.390644227592,45.9932638429023,-0.49593701127224,-1.00512194558077,0.0119285708652738,Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
3836,Westwood - Children (2024),Cognitive training,Children/Adolescents (6-17yo),Exec. functions (report),Endpoint (~12wk),,Very low,G,0.089,"[-0.181, 0.359]",-0.181,0.359,5.17e-01,"[-0.503, 0.682]",3,195,5.84e-02,6.62e-01,no,100,16.612124935399,0.089,-0.181,0.359,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)
3836,Westwood - Children (2024),Cognitive training,Children/Adolescents (6-17yo),Exec. functions (report),Endpoint (~12wk),Parent-rated,Very low,G,0.097,"[-0.16, 0.355]",-0.16,0.355,4.59e-01,"[-0.311, 0.506]",5,238,5.42e-01,7.07e-01,no,76.7716976064676,42.6651350347635,0.097,-0.16,0.355,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)
3836,Westwood - Children (2024),Cognitive training,Children/Adolescents (6-17yo),Core ADHD symptoms [Clinician-rated],Endpoint (~12wk),Clinician-rated,Very low,G,0.116,"[-0.17, 0.402]",-0.17,0.402,4.26e-01,"[-1.74, 1.972]",2,111,NaN,6.62e-01,no,100,100,0.116,-0.17,0.402,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)
3836,Westwood - Children (2024),Cognitive training,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Follow-up (~26wk),Parent-rated,Very low,G,0.132,"[-0.154, 0.418]",-0.154,0.418,3.66e-01,"[-0.599, 0.863]",5,273,6.27e-01,8.33e-01,no,84.7035180566219,45.4594085342668,0.132,-0.154,0.418,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)
3836,Westwood - Children (2024),Cognitive training,Children/Adolescents (6-17yo),Exec. functions (report),Follow-up (~26wk),,Very low,G,0.157,"[-0.116, 0.429]",-0.116,0.429,2.59e-01,"[-0.441, 0.755]",3,195,9.75e-01,7.10e-01,no,100,15.7656742121777,0.157,-0.116,0.429,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks)
3836,Westwood - Children (2024),Cognitive training,Children/Adolescents (6-17yo),Academic/job performance,Endpoint (~12wk),,Very low,G,0.196,"[-0.045, 0.437]",-0.045,0.437,1.11e-01,"[-0.196, 0.588]",4,237,7.06e-01,7.62e-01,no,100,52.9597860239007,0.196,-0.045,0.437,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)
3836,Westwood - Children (2024),Cognitive training,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Endpoint (~12wk),Parent-rated,Very low,G,0.198,"[-0.035, 0.431]",-0.035,0.431,9.61e-02,"[-0.498, 0.894]",10,533,5.56e-01,4.01e-01,no,90.5774548772456,48.8489213744119,0.198,-0.035,0.431,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)
3836,Westwood - Children (2024),Cognitive training,Children/Adolescents (6-17yo),Exec. functions (tests),Follow-up (~26wk),,Very low,G,0.198,"[0.012, 0.384]",0.012,0.384,3.74e-02,"[-0.046, 0.441]",6,374,4.82e-01,8.39e-01,no,86.506901861741,24.5466050250462,0.198,0.012,0.384,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)
3836,Westwood - Children (2024),Cognitive training,Children/Adolescents (6-17yo),Academic/job performance,Follow-up (~26wk),,Very low,G,0.257,"[-0.078, 0.593]",-0.078,0.593,1.33e-01,"[-0.542, 1.057]",4,180,1.61e-01,2.29e-01,no,77.6259786194709,27.6144612268305,0.257,-0.078,0.593,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks)
3836,Westwood - Children (2024),Cognitive training,Children/Adolescents (6-17yo),Exec. functions (report),Follow-up (~26wk),Parent-rated,Very low,G,0.441,"[0.017, 0.865]",0.017,0.865,4.17e-02,"[-2.612, 3.494]",2,82,NaN,2.55e-01,no,41.1346327118526,0,0.441,0.017,0.865,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At follow-up (closest to 26 weeks)
999,Ostinelli (2025),Cognitive training,Adults (>=18yo),Quality of life,Endpoint (~12wk),N/A,Very low,G,-0.309,"[-0.832, 0.214]",-0.832,0.214,2.46e-01,"[-3.698, 3.08]",2,58,NaN,7.06e-01,no,100,100,-0.309,-0.832,0.214,Ostinelli (2025)_Cognitive training_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Cognitive training,Adults (>=18yo),Core ADHD symptoms [Self-rated],Endpoint (~12wk),Self-rated,Very low,G,-0.011,"[-0.332, 0.31]",-0.332,0.31,9.46e-01,"[-0.532, 0.51]",4,160,8.17e-02,6.40e-01,no,100,100,-0.011,-0.332,0.31,Ostinelli (2025)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Cognitive training,Adults (>=18yo),Acceptability,Endpoint (~12wk),,Very low,RR,1.296,"[0.64, 2.623]",0.64,2.623,4.71e-01,"[0.141, 11.918]",3,189,7.02e-01,1.46e-01,no,52.6193874894749,52.6193874894749,0.259282597930083,-0.44628710262842,0.964318700884737,Ostinelli (2025)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
3836,Westwood - Adults (2024),Cognitive training,Adults (>=18yo),Exec. functions (tests),Endpoint (~12wk),,Very low,G,0.412,"[-0.179, 1.003]",-0.179,1.003,1.72e-01,"[-1.447, 2.272]",4,141,4.35e-01,6.45e-01,no,100,27.8455254671894,0.412,-0.179,1.003,Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)
8991,Maiti - Children (2024),Dasotraline,Children/Adolescents (6-17yo),AE (sleep problems),Endpoint (~12wk),,Very low,RR,0.215,"[0.091, 0.508]",0.091,0.508,4.68e-04,"[0.032, 1.424]",3,380,9.02e-01,1.90e-01,no,100,100,-1.53711725085447,-2.39689577246529,-0.677273831403655,Maiti - Children (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)
8991,Maiti - Children (2024),Dasotraline,Children/Adolescents (6-17yo),AE (decreased appetite),Endpoint (~12wk),,Very low,RR,0.307,"[0.128, 0.732]",0.128,0.732,7.76e-03,"[0.045, 2.072]",3,380,3.85e-01,4.90e-01,no,100,100,-1.18090753139494,-2.05572501506252,-0.311974765020826,Maiti - Children (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)
8991,Maiti - Children (2024),Dasotraline,Children/Adolescents (6-17yo),Core ADHD symptoms [Mixed],Endpoint (~12wk),Mixed,Very low,G,0.628,"[0.199, 1.057]",0.199,1.057,4.11e-03,"[-1.076, 2.332]",3,378,4.68e-02,5.89e-01,no,100,100,0.628,0.199,1.057,Maiti - Children (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)
8991,Maiti - Adults (2024),Dasotraline,Adults (>=18yo),AE (decreased appetite),Endpoint (~12wk),,Very low,RR,0.255,"[0.122, 0.532]",0.122,0.532,2.73e-04,"[0.002, 30.074]",2,492,NaN,2.19e-02,no,100,100,-1.36649173382371,-2.10373423424888,-0.631111789640493,Maiti - Adults (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)
8991,Maiti - Adults (2024),Dasotraline,Adults (>=18yo),AE (sleep problems),Endpoint (~12wk),,Very low,RR,0.326,"[0.215, 0.495]",0.215,0.495,1.39e-07,"[0.022, 4.872]",2,492,NaN,3.83e-01,no,100,100,-1.12085789761543,-1.53711725085447,-0.703197516413447,Maiti - Adults (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)
8991,Maiti - Adults (2024),Dasotraline,Adults (>=18yo),Core ADHD symptoms [Mixed],Endpoint (~12wk),Mixed,Very low,G,0.191,"[0.011, 0.371]",0.011,0.371,3.78e-02,"[-0.976, 1.357]",2,482,NaN,8.13e-01,no,100,100,0.191,0.011,0.371,Maiti - Adults (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)
8991,Maiti - Adults (2024),Dasotraline,Adults (>=18yo),CGI,Endpoint (~12wk),N/A,Very low,G,0.234,"[0.003, 0.465]",0.003,0.465,4.68e-02,"[-1.737, 2.206]",2,482,NaN,3.41e-01,no,100,100,0.234,0.003,0.465,Maiti - Adults (2024)_Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks)
575,Catala-Lopez (2017),Desipramine,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Very low,RR,1.221,"[0.299, 4.993]",0.299,4.993,7.81e-01,"[0, 145965.68]",2,114,NaN,6.48e-01,no,100,100,0.199670195128568,-1.20731170559145,1.60803693151847,Catala-Lopez (2017)_Desipramine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
575,Catala-Lopez (2017),Desipramine,Children/Adolescents (6-17yo),Tolerability,Endpoint (~12wk),,Very low,RR,1.416,"[0.098, 20.475]",0.098,20.475,7.98e-01,"[0, 7851599820.018]",2,114,NaN,6.63e-01,no,100,100,0.347835995271528,-2.32278780031157,3.01920462973913,Catala-Lopez (2017)_Desipramine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
2646,Otasowie (2014),Desipramine,Children/Adolescents (6-17yo),Core ADHD symptoms [Teacher-rated],Endpoint (~12wk),Teacher-rated,Very low,G,0.978,"[0.283, 1.673]",0.283,1.673,5.81e-03,"[-5.631, 7.588]",2,89,NaN,8.74e-02,no,100,100,0.978,0.283,1.673,Otasowie (2014)_Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)
2646,Otasowie (2014),Desipramine,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Endpoint (~12wk),Parent-rated,Very low,G,1.431,"[0.859, 2.002]",0.859,2.002,9.33e-07,"[-3.544, 6.405]",2,99,NaN,4.36e-01,no,100,100,1.431,0.859,2.002,Otasowie (2014)_Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Dialectical Behavioral Therapy (DBT),Adults (>=18yo),Acceptability,Endpoint (~12wk),,Low,RR,0.899,"[0.551, 1.468]",0.551,1.468,6.72e-01,"[0.251, 3.227]",3,368,2.10e-01,6.54e-01,no,100,100,-0.106472244510517,-0.596020469829223,0.383900930192324,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Dialectical Behavioral Therapy (DBT),Adults (>=18yo),Core ADHD symptoms [Self-rated],Endpoint (~12wk),Self-rated,Low,G,0.223,"[-0.324, 0.771]",-0.324,0.771,4.24e-01,"[-1.939, 2.386]",3,286,8.55e-01,4.43e-01,no,100,100,0.223,-0.324,0.771,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)
575,Catala-Lopez (2017),Diet (restricted/elimination),Children/Adolescents (6-17yo),Tolerability,Endpoint (~12wk),,Very low,RR,0.371,"[0.04, 3.427]",0.04,3.427,3.82e-01,"[0, 679120.103]",2,127,NaN,6.72e-01,no,100,49.0279987564236,-0.991553216374702,-3.2188758248682,1.23168524289247,Catala-Lopez (2017)_Diet (restricted/elimination)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
575,Catala-Lopez (2017),Diet (restricted/elimination),Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Very low,RR,0.939,"[0.546, 1.615]",0.546,1.615,8.20e-01,"[0.39, 2.264]",4,273,9.03e-02,6.41e-01,no,94.5402404270922,88.8782675366693,-0.0629397997738742,-0.605136303237232,0.47933495667462,Catala-Lopez (2017)_Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
3367,Sonuga-Barke (2014),Diet (restricted/elimination),Children/Adolescents (6-17yo),Core ADHD symptoms [Mixed],Endpoint (~12wk),Mixed,Very low,G,0.729,"[-0.065, 1.524]",-0.065,1.524,7.18e-02,"[-1.97, 3.429]",4,218,1.64e-01,4.72e-01,serious,0,0,0.729,-0.065,1.524,Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)
798,Heirs (2007),Homeopathy,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Endpoint (~12wk),Parent-rated,Very low,G,-0.053,"[-0.515, 0.409]",-0.515,0.409,8.23e-01,"[-3.05, 2.944]",2,63,NaN,6.09e-01,no,0,0,-0.053,-0.515,0.409,Heirs (2007)_Homeopathy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)
798,Heirs (2007),Homeopathy,Children/Adolescents (6-17yo),CD/ODD symptoms,Endpoint (~12wk),Parent-rated,Very low,G,0.021,"[-0.442, 0.484]",-0.442,0.484,9.29e-01,"[-2.982, 3.024]",2,63,NaN,5.94e-01,no,0,0,0.021,-0.442,0.484,Heirs (2007)_Homeopathy_Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)
575,Catala-Lopez (2017),Homeopathy,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Very low,RR,1.448,"[0.73, 2.874]",0.73,2.874,2.90e-01,"[0.017, 123.252]",2,104,NaN,6.92e-01,no,18.6210952873151,18.6210952873151,0.370183293963525,-0.3147107448397,1.05570478765683,Catala-Lopez (2017)_Homeopathy_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
3448,Sugaya (2023),Methylphenidate,Pre-school (<6yo),Acceptability,Endpoint (~12wk),,Very low,RR,2.888,"[1.55, 5.382]",1.55,5.382,8.38e-04,"[0.051, 163.305]",2,216,NaN,5.64e-01,no,100,100,1.06056422103058,0.438254930931155,1.68306005230471,Sugaya (2023)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
662,Chiu (2022),Methylphenidate,Pre-school (<6yo),Core ADHD symptoms [Parent-rated],Endpoint (~12wk),Parent-rated,Very low,G,0.628,"[0.282, 0.974]",0.282,0.974,3.72e-04,"[-0.409, 1.665]",5,623,2.75e-01,1.05e-01,no,100,100,0.628,0.282,0.974,Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)
662,Chiu (2022),Methylphenidate,Pre-school (<6yo),Core ADHD symptoms [Teacher-rated],Endpoint (~12wk),Teacher-rated,Very low,G,0.664,"[0.222, 1.106]",0.222,1.106,3.25e-03,"[-0.669, 1.997]",5,526,8.48e-02,1.12e-01,no,100,100,0.664,0.222,1.106,Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Methylphenidate,Children/Adolescents (6-17yo),Tolerability,Endpoint (~12wk),,High,RR,0.638,"[0.363, 1.122]",0.363,1.122,1.19e-01,"[0.349, 1.166]",20,2878,5.23e-01,8.55e-01,no,100,100,-0.449416995637347,-1.01335244471729,0.115112807100505,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Methylphenidate,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,High,RR,1.584,"[1.353, 1.854]",1.353,1.854,1.01e-08,"[1.34, 1.873]",21,2947,1.12e-01,5.98e-01,no,100,100,0.459953293392234,0.302324349188651,0.617345467143664,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Methylphenidate,Children/Adolescents (6-17yo),Core ADHD symptoms [Clinician-rated],Endpoint (~12wk),Clinician-rated,High,G,0.762,"[0.56, 0.965]",0.56,0.965,1.45e-13,"[0.328, 1.197]",6,1038,8.63e-01,2.46e-01,no,100,100,0.762,0.56,0.965,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Methylphenidate,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Endpoint (~12wk),Parent-rated,High,G,0.786,"[0.634, 0.939]",0.634,0.939,4.69e-24,"[0.603, 0.97]",8,852,3.33e-01,6.24e-01,no,100,100,0.786,0.634,0.939,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)
3425,Storebo (2023),Methylphenidate,Children/Adolescents (6-17yo),Suicidal ideation/behavior,Endpoint (~12wk),N/A,Moderate,RR,1.103,"[0.245, 4.962]",0.245,4.962,8.98e-01,"[0.154, 7.927]",6,1032,2.71e-02,6.62e-01,no,77.3979672231714,77.3979672231714,0.0980337402713654,-1.40649706843741,1.60180888526961,Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Methylphenidate,Children/Adolescents (6-17yo),Core ADHD symptoms [Teacher-rated],Endpoint (~12wk),Teacher-rated,Moderate,G,0.826,"[0.625, 1.028]",0.625,1.028,9.89e-16,"[0.474, 1.179]",5,437,4.68e-01,9.28e-01,no,100,100,0.826,0.625,1.028,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)
8992,Farhat (2024),Methylphenidate,Children/Adolescents (6-17yo),Tics/Tourette disorder symptoms,Endpoint (~12wk),N/A,Low,G,0.117,"[-0.388, 0.622]",-0.388,0.622,6.49e-01,"[-1.825, 2.06]",3,217,8.90e-01,5.27e-01,no,100,100,0.117,-0.388,0.622,Farhat (2024)_Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)
3425,Storebo (2023),Methylphenidate,Children/Adolescents (6-17yo),Quality of life,Endpoint (~12wk),N/A,Low,G,0.61,"[0.421, 0.798]",0.421,0.798,2.29e-10,"[0.196, 1.023]",3,514,5.21e-01,1.35e-01,no,100,100,0.61,0.421,0.798,Storebo (2023)_Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)
3425,Storebo (2023),Methylphenidate,Children/Adolescents (6-17yo),AE (decreased appetite),Endpoint (~12wk),,Low,RR,0.264,"[0.193, 0.363]",0.193,0.363,1.91e-16,"[0.059, 1.183]",41,6091,1.90e-03,1.14e-05,no,85.285965820091,78.4944522568523,-1.33180617583582,-1.64506509007725,-1.01335244471729,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)
3425,Storebo (2023),Methylphenidate,Children/Adolescents (6-17yo),AE (sleep problems),Endpoint (~12wk),,Very low,RR,0.533,"[0.396, 0.718]",0.396,0.718,3.50e-05,"[0.137, 2.082]",37,5499,1.91e-02,2.80e-01,no,88.0648044370761,81.7439304049397,-0.629233854816293,-0.926341067727656,-0.331285709933913,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)
474,Bryant (2021),Methylphenidate,Children/Adolescents (6-17yo),Generalized anxiety,Endpoint (~12wk),N/A,Very low,G,0.382,"[-0.215, 0.979]",-0.215,0.979,2.09e-01,"[-1.893, 2.657]",3,162,1.78e-01,4.18e-01,no,100,100,0.382,-0.215,0.979,Bryant (2021)_Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)
3425,Storebo (2023),Methylphenidate,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Follow-up (~26wk),Parent-rated,Very low,G,0.567,"[0.347, 0.786]",0.347,0.786,4.20e-07,"[-0.856, 1.99]",2,322,NaN,8.51e-01,no,100,0,0.567,0.347,0.786,Storebo (2023)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)
999,Ostinelli (2025),Methylphenidate,Adults (>=18yo),Tolerability,Endpoint (~12wk),,High,RR,0.499,"[0.361, 0.69]",0.361,0.69,2.58e-05,"[0.354, 0.705]",21,4389,7.46e-01,5.14e-01,no,93.979124818247,93.979124818247,-0.695149183230618,-1.01887732064926,-0.371063681390832,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Methylphenidate,Adults (>=18yo),Core ADHD symptoms [Self-rated],Endpoint (~12wk),Self-rated,High,G,0.343,"[0.261, 0.425]",0.261,0.425,3.01e-16,"[0.251, 0.434]",13,2944,1.40e-01,4.15e-01,no,100,100,0.343,0.261,0.425,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)
2785,Pievsky (2018),Methylphenidate,Adults (>=18yo),Exec. functions (tests),Endpoint (~12wk),Clinician-rated,Moderate,G,0.154,"[0.028, 0.28]",0.028,0.28,1.62e-02,"[-0.014, 0.322]",15,973,3.83e-01,6.21e-01,no,87.1818731745766,80.6955846073525,0.154,0.028,0.28,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Methylphenidate,Adults (>=18yo),Core ADHD symptoms [Clinician-rated],Endpoint (~12wk),Clinician-rated,Moderate,G,0.502,"[0.393, 0.611]",0.393,0.611,1.82e-19,"[0.153, 0.85]",18,3680,2.04e-02,7.16e-02,no,100,100,0.502,0.393,0.611,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)
381,Boesen (2022),Methylphenidate,Adults (>=18yo),AE (decreased appetite),Endpoint (~12wk),,Very low,RR,0.245,"[0.201, 0.3]",0.201,0.3,5.06e-43,"[0.197, 0.305]",16,4491,2.45e-01,4.87e-01,no,20.4896803774332,20.4896803774332,-1.40649706843741,-1.60445037092306,-1.20397280432594,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)
381,Boesen (2022),Methylphenidate,Adults (>=18yo),AE (sleep problems),Endpoint (~12wk),,Very low,RR,0.512,"[0.394, 0.665]",0.394,0.665,5.18e-07,"[0.361, 0.726]",16,4435,3.61e-02,2.09e-01,no,18.3663455629569,18.3663455629569,-0.669430653942629,-0.931404369684203,-0.407968238326283,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Methylphenidate,Adults (>=18yo),Quality of life,Endpoint (~12wk),N/A,Low,G,-0.088,"[-0.277, 0.1]",-0.277,0.1,3.59e-01,"[-1.312, 1.135]",2,490,NaN,6.76e-01,no,100,100,-0.088,-0.277,0.1,Ostinelli (2025)_Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Methylphenidate,Adults (>=18yo),Acceptability,Endpoint (~12wk),,Very low,RR,0.999,"[0.819, 1.219]",0.819,1.219,9.93e-01,"[0.563, 1.774]",20,3925,6.23e-01,9.32e-02,no,100,100,-0.00100050033358353,-0.199671195129068,0.198030850499135,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Methylphenidate,Adults (>=18yo),Exec. functions (tests),Endpoint (~12wk),N/A,Very low,G,0.152,"[-0.3, 0.604]",-0.3,0.604,5.09e-01,"[-2.778, 3.083]",2,71,NaN,6.47e-01,no,100,100,0.152,-0.3,0.604,Ostinelli (2025)_Methylphenidate_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Methylphenidate,Adults (>=18yo),Core ADHD symptoms [Self-rated],Follow-up (~26wk),Self-rated,Very low,G,0.255,"[0.071, 0.44]",0.071,0.44,6.66e-03,"[-0.941, 1.452]",2,498,NaN,4.70e-01,no,100,100,0.255,0.071,0.44,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)
999,Ostinelli (2025),Methylphenidate,Adults (>=18yo),Core ADHD symptoms [Clinician-rated],Follow-up (~26wk),Clinician-rated,Very low,G,0.338,"[0.155, 0.522]",0.155,0.522,2.97e-04,"[-0.85, 1.527]",2,506,NaN,7.22e-01,no,100,100,0.338,0.155,0.522,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)
999,Ostinelli (2025),Methylphenidate,Adults (>=18yo),Emotional dysregulation,Endpoint (~12wk),N/A,Very low,G,0.431,"[-0.013, 0.875]",-0.013,0.875,5.72e-02,"[-1.393, 2.254]",3,655,4.22e-01,3.60e-01,no,100,100,0.431,-0.013,0.875,Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)
2785,Pievsky (2018),Methylphenidate,Adults (>=18yo),Driving,Endpoint (~12wk),Clinician-rated,Very low,G,0.53,"[-0.073, 1.133]",-0.073,1.133,8.49e-02,"[-1.706, 2.766]",3,154,3.09e-02,4.67e-01,no,64.920685512261,45.7264203269862,0.53,-0.073,1.133,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)
1056,Elliott (2020),Methylphenidate,Adults (>=18yo),Exec. functions (report),Endpoint (~12wk),Self-rated,Very low,G,0.647,"[-0.021, 1.316]",-0.021,1.316,5.78e-02,"[-1.586, 2.881]",5,1579,3.67e-01,1.98e-02,no,0,0,0.647,-0.021,1.316,Elliott (2020)_Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)
529,Candido (2021),Methylphenidate,Adults (>=18yo),CGI,Endpoint (~12wk),Clinician-rated,Very low,G,0.701,"[-0.13, 1.532]",-0.13,1.532,9.81e-02,"[-8.068, 9.47]",2,139,NaN,5.91e-01,no,0,0,0.701,-0.13,1.532,Candido (2021)_Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)
575,Catala-Lopez (2017),Methylphenidate + Alpha-2 agonists,Children/Adolescents (6-17yo),Tolerability,Endpoint (~12wk),,Very low,RR,0.349,"[0.037, 3.27]",0.037,3.27,3.57e-01,"[0, 694035.551]",2,127,NaN,6.77e-01,no,100,100,-1.05268335677971,-3.29683736633791,1.18478998490916,Catala-Lopez (2017)_Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
575,Catala-Lopez (2017),Methylphenidate + Alpha-2 agonists,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Very low,RR,2.419,"[1.376, 4.251]",1.376,4.251,2.15e-03,"[0.062, 93.671]",2,127,NaN,5.52e-01,no,100,100,0.88335423162789,0.319180739511152,1.44715424937665,Catala-Lopez (2017)_Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
4036,Zhang (2023),Mindfulness,Children/Adolescents (6-17yo),Core ADHD symptoms [Mixed],Endpoint (~12wk),Mixed,Very low,G,0.169,"[-0.057, 0.394]",-0.057,0.394,1.42e-01,"[-0.197, 0.535]",4,257,4.97e-02,7.44e-01,no,39.6165445484996,39.6165445484996,0.169,-0.057,0.394,Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)
4036,Zhang (2023),Mindfulness,Children/Adolescents (6-17yo),Exec. functions (mixed),Endpoint (~12wk),N/A,Very low,G,0.444,"[-0.083, 0.972]",-0.083,0.972,9.85e-02,"[-1.503, 2.392]",3,187,4.02e-01,4.81e-01,no,42.643410546435,42.643410546435,0.444,-0.083,0.972,Zhang (2023)_Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Mindfulness,Adults (>=18yo),Acceptability,Endpoint (~12wk),,Very low,RR,0.24,"[0.03, 1.91]",0.03,1.91,1.77e-01,"[0.001, 87.349]",4,301,4.60e-01,4.99e-01,no,100,100,-1.42711635564015,-3.50655789731998,0.647103242058538,Ostinelli (2025)_Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
2118,Liu (2023),Mindfulness,Adults (>=18yo),Quality of life,Endpoint (~12wk),N/A,Very low,G,-0.119,"[-0.391, 0.152]",-0.391,0.152,3.90e-01,"[-2.024, 1.786]",2,223,NaN,6.82e-01,no,100,46.472956206507,-0.119,-0.391,0.152,Liu (2023)_Mindfulness_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Mindfulness,Adults (>=18yo),Emotional dysregulation,Endpoint (~12wk),N/A,Very low,G,0.129,"[-0.481, 0.738]",-0.481,0.738,6.79e-01,"[-5.477, 5.734]",2,103,NaN,7.64e-01,no,100,100,0.129,-0.481,0.738,Ostinelli (2025)_Mindfulness_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)
2118,Liu (2023),Mindfulness,Adults (>=18yo),Depressive disorder symptoms,Endpoint (~12wk),N/A,Very low,G,0.48,"[0.015, 0.945]",0.015,0.945,4.33e-02,"[-3.853, 4.812]",2,157,NaN,4.92e-01,no,100,58.0392100321135,0.48,0.015,0.945,Liu (2023)_Mindfulness_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)
2157,Lopez-Pinar (2019),Mindfulness,Adults (>=18yo),Generalized anxiety,Endpoint (~12wk),Self-rated,Very low,G,0.725,"[-0.297, 1.747]",-0.297,1.747,1.65e-01,"[-10.453, 11.903]",2,137,NaN,5.93e-01,no,100,0,0.725,-0.297,1.747,Lopez-Pinar (2019)_Mindfulness_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Mindfulness,Adults (>=18yo),Exec. functions (tests),Endpoint (~12wk),N/A,Very low,G,0.761,"[-0.304, 1.826]",-0.304,1.826,1.62e-01,"[-10.274, 11.796]",2,74,NaN,6.61e-01,no,100,100,0.761,-0.304,1.826,Ostinelli (2025)_Mindfulness_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Mindfulness,Adults (>=18yo),Exec. functions (tests),Follow-up (~26wk),N/A,Very low,G,0.826,"[0.099, 1.553]",0.099,1.553,2.60e-02,"[-6.727, 8.379]",2,162,NaN,5.86e-02,no,100,100,0.826,0.099,1.553,Ostinelli (2025)_Mindfulness_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks)
999,Ostinelli (2025),Mindfulness,Adults (>=18yo),Core ADHD symptoms [Self-rated],Follow-up (~26wk),Self-rated,Very low,G,0.86,"[0.408, 1.312]",0.408,1.312,1.90e-04,"[-3.211, 4.932]",2,162,NaN,2.96e-01,no,100,100,0.86,0.408,1.312,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)
999,Ostinelli (2025),Mindfulness,Adults (>=18yo),Core ADHD symptoms [Self-rated],Endpoint (~12wk),Self-rated,Very low,G,0.928,"[0.423, 1.433]",0.423,1.433,3.14e-04,"[-0.645, 2.501]",4,264,9.74e-02,9.42e-03,no,100,100,0.928,0.423,1.433,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Mindfulness,Adults (>=18yo),Core ADHD symptoms [Clinician-rated],Endpoint (~12wk),Clinician-rated,Very low,G,1.115,"[0.053, 2.178]",0.053,2.178,3.97e-02,"[-3.302, 5.533]",3,210,1.61e-01,2.83e-03,no,100,100,1.115,0.053,2.178,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Modafinil,Children/Adolescents (6-17yo),Tolerability,Endpoint (~12wk),,Moderate,RR,0.793,"[0.359, 1.751]",0.359,1.751,5.65e-01,"[0.28, 2.242]",6,809,1.04e-01,6.94e-01,no,100,100,-0.231932057347289,-1.02443289049386,0.560187053303715,Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Modafinil,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Endpoint (~12wk),Parent-rated,Low,G,0.468,"[0.311, 0.626]",0.311,0.626,5.67e-09,"[0.212, 0.724]",4,722,4.26e-01,6.73e-01,no,100,100,0.468,0.311,0.626,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Modafinil,Children/Adolescents (6-17yo),Core ADHD symptoms [Clinician-rated],Endpoint (~12wk),Clinician-rated,Low,G,0.489,"[0.337, 0.641]",0.337,0.641,2.86e-10,"[0.274, 0.705]",5,768,8.79e-02,5.73e-02,no,100,100,0.489,0.337,0.641,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Modafinil,Children/Adolescents (6-17yo),Core ADHD symptoms [Teacher-rated],Endpoint (~12wk),Teacher-rated,Low,G,0.534,"[0.35, 0.717]",0.35,0.717,1.26e-08,"[0.235, 0.832]",4,524,2.62e-01,6.55e-01,no,100,100,0.534,0.35,0.717,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)
757,Cortese - Children (2018),Modafinil,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Very low,RR,1.299,"[1.01, 1.671]",1.01,1.671,4.13e-02,"[0.787, 2.146]",6,809,2.54e-01,2.83e-01,no,100,100,0.261594737688462,0.00995033085316809,0.513422249613257,Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),Modafinil,Adults (>=18yo),Core ADHD symptoms [Self-rated],Endpoint (~12wk),Self-rated,Very low,G,0.434,"[-0.549, 1.416]",-0.549,1.416,3.87e-01,"[-10.144, 11.011]",2,257,NaN,2.61e-01,no,100,100,0.434,-0.549,1.416,Ostinelli (2025)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)
575,Catala-Lopez (2017),Multimodal behavioral interventions,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Very low,RR,1.393,"[0.549, 3.538]",0.549,3.538,4.85e-01,"[0.195, 9.969]",5,584,2.95e-01,7.42e-01,no,75.0093731386266,0,0.331459694797669,-0.599656837472606,1.26356159573759,Catala-Lopez (2017)_Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
998,Westwood - Children (2025),Neurofeedback,Children/Adolescents (6-17yo),Core ADHD symptoms [Clinician-rated],Endpoint (~12wk),Clinician-rated,Very low,G,-0.131,"[-0.448, 0.187]",-0.448,0.187,4.20e-01,"[-1.032, 0.771]",3,274,3.50e-01,7.52e-01,no,100,24.0760242005093,-0.131,-0.448,0.187,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)
998,Westwood - Children (2025),Neurofeedback,Children/Adolescents (6-17yo),Exec. functions (tests),Follow-up (~26wk),,Very low,G,0.025,"[-0.196, 0.246]",-0.196,0.246,8.22e-01,"[-0.46, 0.511]",3,279,9.75e-01,6.25e-01,no,100,27.798985531637,0.025,-0.196,0.246,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)
998,Westwood - Children (2025),Neurofeedback,Children/Adolescents (6-17yo),Exec. functions (tests),Endpoint (~12wk),,Very low,G,0.043,"[-0.075, 0.162]",-0.075,0.162,4.74e-01,"[-0.085, 0.172]",17,920,8.99e-02,5.31e-02,no,100,23.4975188773652,0.043,-0.075,0.162,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)
998,Westwood - Children (2025),Neurofeedback,Children/Adolescents (6-17yo),Core ADHD symptoms [Teacher-rated],Endpoint (~12wk),Teacher-rated,Low,G,0.134,"[-0.008, 0.276]",-0.008,0.276,6.53e-02,"[-0.03, 0.297]",10,587,9.93e-01,4.60e-01,no,100,50.6425094044967,0.134,-0.008,0.276,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)
998,Westwood - Children (2025),Neurofeedback,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Follow-up (~52wk),Parent-rated,Very low,G,0.165,"[-0.157, 0.487]",-0.157,0.487,3.15e-01,"[-1.922, 2.252]",2,121,NaN,6.80e-01,no,100,100,0.165,-0.157,0.487,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks
575,Catala-Lopez (2017),Neurofeedback,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Very low,RR,1.489,"[0.877, 2.527]",0.877,2.527,1.40e-01,"[0.769, 2.882]",7,333,6.54e-01,7.79e-01,no,100,26.684835871474,0.398104753701872,-0.131248286609954,0.927032828406057,Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
998,Westwood - Children (2025),Neurofeedback,Children/Adolescents (6-17yo),Exec. functions (report),Endpoint (~12wk),,Very low,G,0.23,"[-0.075, 0.535]",-0.075,0.535,1.39e-01,"[-1.772, 2.232]",2,125,NaN,7.55e-01,no,100,0,0.23,-0.075,0.535,Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)
998,Westwood - Children (2025),Neurofeedback,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Follow-up (~26wk),Parent-rated,Very low,G,0.296,"[-0.012, 0.604]",-0.012,0.604,5.94e-02,"[-0.602, 1.194]",4,314,5.95e-01,7.81e-02,no,100,24.3157158207165,0.296,-0.012,0.604,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)
998,Westwood - Children (2025),Neurofeedback,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Endpoint (~12wk),Parent-rated,Very low,G,0.421,"[0.236, 0.606]",0.236,0.606,8.37e-06,"[-0.242, 1.084]",19,1195,5.17e-03,1.75e-01,no,100,21.7124510399631,0.421,0.236,0.606,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)
998,Westwood - Children (2025),Neurofeedback,Children/Adolescents (6-17yo),Exec. functions (report),Endpoint (~12wk),Parent-rated,Very low,G,0.429,"[0.077, 0.781]",0.077,0.781,1.68e-02,"[-0.345, 1.203]",3,126,2.29e-01,4.32e-01,no,100,0,0.429,0.077,0.781,Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)
998,Westwood - Adults (2025),Neurofeedback,Adults (>=18yo),Exec. functions (tests),Endpoint (~12wk),Self-rated,Very low,G,0.126,"[-0.306, 0.558]",-0.306,0.558,5.67e-01,"[-2.673, 2.925]",2,59,NaN,6.31e-01,no,100,22.9045463269426,0.126,-0.306,0.558,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)
998,Westwood - Adults (2025),Neurofeedback,Adults (>=18yo),Core ADHD symptoms [Self-rated],Endpoint (~12wk),Self-rated,Very low,G,0.592,"[0.062, 1.121]",0.062,1.121,2.85e-02,"[-2.84, 4.024]",2,54,NaN,2.58e-01,no,100,25.9732078877436,0.592,0.062,1.121,Westwood - Adults (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)
343,Bikic (2017),Organizational skills interventions,Children/Adolescents (6-17yo),Academic/job performance,Endpoint (~12wk),Teacher-rated,Very low,G,0.311,"[0.174, 0.448]",0.174,0.448,8.84e-06,"[0.103, 0.518]",11,929,3.73e-01,7.38e-01,serious,100,4.76405841866378,0.311,0.174,0.448,Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)
973,Doffer - Preschool (2023),Parent-mediated behavioral interventions,Pre-school (<6yo),Core ADHD symptoms [Parent-rated],Follow-up (~26wk),Parent-rated,Very low,G,0.216,"[-0.28, 0.711]",-0.28,0.711,3.94e-01,"[-1.02, 1.451]",3,164,3.94e-01,5.40e-02,no,100,100,0.216,-0.28,0.711,Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)
9002,Groenman - Preschool (2022),Parent-mediated behavioral interventions,Pre-school (<6yo),Conduct disorder symptoms (CD),Endpoint (~12wk),Parent-rated,Very low,G,0.241,"[-0.097, 0.579]",-0.097,0.579,1.62e-01,"[-0.912, 1.394]",3,315,5.33e-01,3.64e-01,no,100,64.044146634404,0.241,-0.097,0.579,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)
9002,Groenman - Preschool (2022),Parent-mediated behavioral interventions,Pre-school (<6yo),Oppositional symptoms (ODD),Endpoint (~12wk),Parent-rated,Very low,G,0.242,"[0.005, 0.479]",0.005,0.479,4.56e-02,"[-0.279, 0.763]",3,305,8.18e-01,2.82e-01,no,100,52.1601206564876,0.242,0.005,0.479,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)
9002,Groenman - Preschool (2022),Parent-mediated behavioral interventions,Pre-school (<6yo),Core ADHD symptoms [Parent-rated],Endpoint (~12wk),Parent-rated,Very low,G,0.634,"[0.248, 1.019]",0.248,1.019,1.28e-03,"[-0.483, 1.75]",5,399,1.37e-01,4.03e-01,no,100,41.7763734170466,0.634,0.248,1.019,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)
575,Catala-Lopez (2017),Parent-mediated behavioral interventions,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Low,RR,1.007,"[0.632, 1.605]",0.632,1.605,9.77e-01,"[0.289, 3.508]",12,1123,3.08e-01,5.75e-01,serious,74.1735687045305,51.8218883937701,0.00697561373642514,-0.45886588483528,0.473123756581979,Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
9002,Groenman (2022),Parent-mediated behavioral interventions,Children/Adolescents (6-17yo),Conduct disorder symptoms (CD),Endpoint (~12wk),Parent-rated,Low,G,0.164,"[0.059, 0.269]",0.059,0.269,2.12e-03,"[0.047, 0.282]",12,1428,8.37e-01,7.16e-01,no,79.1250384149832,8.68748256708517,0.164,0.059,0.269,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)
973,Doffer (2023),Parent-mediated behavioral interventions,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Follow-up (~52wk),Parent-rated,Very low,G,0.238,"[0.034, 0.442]",0.034,0.442,2.21e-02,"[-0.209, 0.685]",4,571,1.36e-02,9.00e-01,no,100,0,0.238,0.034,0.442,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks
9002,Groenman (2022),Parent-mediated behavioral interventions,Children/Adolescents (6-17yo),Oppositional symptoms (ODD),Endpoint (~12wk),Parent-rated,Very low,G,0.249,"[0.113, 0.385]",0.113,0.385,3.47e-04,"[-0.098, 0.595]",13,1439,3.68e-01,8.09e-01,no,82.7127524903624,11.1956949163865,0.249,0.113,0.385,Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)
973,Doffer (2023),Parent-mediated behavioral interventions,Children/Adolescents (6-17yo),Oppositional symptoms (ODD),Follow-up (~26wk),Parent-rated,Very low,G,0.303,"[-0.017, 0.623]",-0.017,0.623,6.35e-02,"[-1.773, 2.379]",2,149,NaN,7.97e-01,no,100,60.5465959285286,0.303,-0.017,0.623,Doffer (2023)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks)
9002,Groenman (2022),Parent-mediated behavioral interventions,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Endpoint (~12wk),Parent-rated,Very low,G,0.345,"[0.136, 0.554]",0.136,0.554,1.21e-03,"[-0.448, 1.138]",16,1625,3.81e-01,4.98e-01,no,87.2180264060818,16.2075574534128,0.345,0.136,0.554,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)
3228,Seiffer (2022),Physical training,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Very low,RR,1.096,"[0.577, 2.079]",0.577,2.079,7.80e-01,"[0.172, 6.985]",6,232,7.02e-01,2.14e-01,no,100,13.5277305790199,0.0916671885258239,-0.549913012474038,0.731887008875876,Seiffer (2022)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
3228,Seiffer (2022),Physical training,Children/Adolescents (6-17yo),Core ADHD symptoms [Mixed],Endpoint (~12wk),Mixed,Very low,G,0.487,"[0.225, 0.748]",0.225,0.748,2.62e-04,"[0.008, 0.966]",9,302,9.41e-01,4.89e-01,no,100,27.8667984783578,0.487,0.225,0.748,Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)
3228,Seiffer (2022),Physical training,Children/Adolescents (6-17yo),Social-communication skills,Endpoint (~12wk),N/A,Very low,G,0.494,"[-0.41, 1.398]",-0.41,1.398,2.84e-01,"[-2.358, 3.346]",4,90,6.16e-01,6.07e-01,no,100,16.4490499242549,0.494,-0.41,1.398,Seiffer (2022)_Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)
1598,Huang (2022),Physical training,Children/Adolescents (6-17yo),Exec. functions (tests),Endpoint (~12wk),Clinician-rated,Very low,G,0.953,"[0.636, 1.27]",0.636,1.27,3.88e-09,"[-0.199, 2.105]",16,445,7.05e-01,8.96e-01,no,43.8046695750292,0,0.953,0.636,1.27,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)
1318,Gillies (2023),Polyunsaturated fatty acids,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Follow-up (~26wk),Parent-rated,Low,G,0.049,"[-0.101, 0.198]",-0.101,0.198,5.21e-01,"[-0.343, 0.44]",15,963,7.65e-02,4.49e-01,no,84.5651204115789,73.9719193475941,0.049,-0.101,0.198,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)
1318,Gillies (2023),Polyunsaturated fatty acids,Children/Adolescents (6-17yo),Core ADHD symptoms [Teacher-rated],Endpoint (~12wk),Teacher-rated,Very low,G,-0.371,"[-1.094, 0.353]",-1.094,0.353,3.15e-01,"[-2.772, 2.03]",4,185,6.69e-01,1.61e-01,no,47.1166628928182,47.1166628928182,-0.371,-1.094,0.353,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)
1318,Gillies (2023),Polyunsaturated fatty acids,Children/Adolescents (6-17yo),Core ADHD symptoms [Parent-rated],Endpoint (~12wk),Parent-rated,Very low,G,-0.258,"[-0.558, 0.043]",-0.558,0.043,9.25e-02,"[-0.958, 0.442]",5,329,8.21e-01,5.72e-01,no,77.5911778580491,55.980411244828,-0.258,-0.558,0.043,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)
1318,Gillies (2023),Polyunsaturated fatty acids,Children/Adolescents (6-17yo),Conduct disorder symptoms (CD),Follow-up (~26wk),N/A,Very low,G,-0.111,"[-0.319, 0.097]",-0.319,0.097,2.95e-01,"[-0.406, 0.183]",5,332,8.71e-01,7.24e-01,no,66.4848836348154,66.4848836348154,-0.111,-0.319,0.097,Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)
1318,Gillies (2023),Polyunsaturated fatty acids,Children/Adolescents (6-17yo),Oppositional symptoms (ODD),Follow-up (~26wk),N/A,Very low,G,-0.105,"[-0.293, 0.084]",-0.293,0.084,2.78e-01,"[-0.372, 0.163]",5,423,7.53e-01,7.27e-01,no,54.2611239105427,54.2611239105427,-0.105,-0.293,0.084,Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)
1318,Gillies (2023),Polyunsaturated fatty acids,Children/Adolescents (6-17yo),Social-communication skills,Follow-up (~26wk),N/A,Very low,G,-0.095,"[-0.409, 0.219]",-0.409,0.219,5.52e-01,"[-2.13, 1.939]",2,145,NaN,6.39e-01,no,64.568526389048,64.568526389048,-0.095,-0.409,0.219,Gillies (2023)_Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)
575,Catala-Lopez (2017),Polyunsaturated fatty acids,Children/Adolescents (6-17yo),Tolerability,Endpoint (~12wk),,Very low,RR,0.891,"[0.311, 2.553]",0.311,2.553,8.29e-01,"[0.156, 5.072]",7,584,1.46e-01,6.97e-01,no,39.0526951337376,39.0526951337376,-0.115410851511328,-1.1679623668029,0.937269138259347,Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
1318,Gillies (2023),Polyunsaturated fatty acids,Children/Adolescents (6-17yo),Core ADHD symptoms [Teacher-rated],Follow-up (~26wk),Teacher-rated,Low,G,-0.061,"[-0.242, 0.12]",-0.242,0.12,5.11e-01,"[-0.32, 0.199]",6,498,5.90e-01,9.46e-02,no,76.1271942755267,76.1271942755267,-0.061,-0.242,0.12,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)
1318,Gillies (2023),Polyunsaturated fatty acids,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Very low,RR,0.898,"[0.659, 1.225]",0.659,1.225,4.97e-01,"[0.618, 1.306]",8,603,8.71e-01,7.20e-01,no,50.5297731071172,50.5297731071172,-0.107585210679937,-0.41703174447963,0.20294084399669,Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
1459,Handel (2021),Polyunsaturated fatty acids,Children/Adolescents (6-17yo),Quality of life,Follow-up (~26wk),N/A,Very low,G,-0.014,"[-0.31, 0.281]",-0.31,0.281,9.24e-01,"[-1.929, 1.9]",2,188,NaN,5.96e-01,no,30.7475458682863,0,-0.014,-0.31,0.281,Handel (2021)_Polyunsaturated fatty acids_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks)
1318,Gillies (2023),Polyunsaturated fatty acids,Children/Adolescents (6-17yo),AE (sleep problems),Endpoint (~12wk),,Very low,RR,3.035,"[0.292, 31.549]",0.292,31.549,3.53e-01,"[0, 7061584765.746]",2,122,NaN,7.62e-01,no,40.2735059333428,0,1.11021142451146,-1.23100147671386,3.45154189276382,Gillies (2023)_Polyunsaturated fatty acids_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)
9001,Liang (2024),Probiotics,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Low,RR,0.926,"[0.503, 1.704]",0.503,1.704,8.04e-01,"[0.283, 3.03]",4,224,5.64e-01,6.73e-01,no,100,100,-0.0768810443359576,-0.687165108882398,0.532978428407124,Liang (2024)_Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
9001,Liang (2024),Probiotics,Children/Adolescents (6-17yo),Core ADHD symptoms [Mixed],Endpoint (~12wk),Mixed,Low,G,0.351,"[-0.108, 0.81]",-0.108,0.81,1.34e-01,"[-0.997, 1.699]",5,220,4.15e-01,7.10e-01,no,100,100,0.351,-0.108,0.81,Liang (2024)_Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)
575,Catala-Lopez (2017),Risperidone,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Very low,RR,0.662,"[0.377, 1.163]",0.377,1.163,1.51e-01,"[0.017, 25.456]",2,193,NaN,7.38e-01,no,95.5175564439777,95.5175564439777,-0.412489723045129,-0.975510091534126,0.151002873536527,Catala-Lopez (2017)_Risperidone_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
3419,Storebo (2019),Social skill training,Children/Adolescents (6-17yo),Social-communication skills,Follow-up (~26wk),N/A,Very low,G,0.122,"[-0.31, 0.554]",-0.31,0.554,5.80e-01,"[-2.678, 2.922]",2,73,NaN,6.36e-01,no,71.5672985698046,71.5672985698046,0.122,-0.31,0.554,Storebo (2019)_Social skill training_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)
3419,Storebo (2019),Social skill training,Children/Adolescents (6-17yo),Social-communication skills,Endpoint (~12wk),N/A,Very low,G,0.253,"[0.022, 0.483]",0.022,0.483,3.17e-02,"[-0.074, 0.579]",5,270,2.64e-01,8.23e-01,no,92.23786817193,20.0189068026051,0.253,0.022,0.483,Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)
3419,Storebo (2019),Social skill training,Children/Adolescents (6-17yo),Core ADHD symptoms [Teacher-rated],Endpoint (~12wk),Teacher-rated,Very low,G,0.54,"[-0.918, 1.999]",-0.918,1.999,4.68e-01,"[-15.3, 16.381]",2,83,NaN,3.66e-01,no,100,51.8029894781456,0.54,-0.918,1.999,Storebo (2019)_Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)
8996,Yin - children (2024),tDCS,Children/Adolescents (6-17yo),Exec. functions (tests),Endpoint (~12wk),N/A,Low,G,0.148,"[-0.044, 0.339]",-0.044,0.339,1.30e-01,"[-0.07, 0.366]",11,370,8.90e-01,3.91e-01,no,78.3341189793422,70.2590809203003,0.148,-0.044,0.339,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)
8996,Yin - children (2024),tDCS,Children/Adolescents (6-17yo),Core ADHD symptoms [Mixed],Endpoint (~12wk),Mixed,Very low,G,-0.217,"[-0.786, 0.351]",-0.786,0.351,4.54e-01,"[-4.85, 4.415]",2,60,NaN,7.00e-01,no,100,100,-0.217,-0.786,0.351,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)
8996,Yin - adults (2024),tDCS,Adults (>=18yo),Core ADHD symptoms [Mixed],Endpoint (~12wk),Mixed,Low,G,0.433,"[0.177, 0.689]",0.177,0.689,9.30e-04,"[0.07, 0.796]",5,217,5.55e-01,6.83e-01,no,100,68.6351753527595,0.433,0.177,0.689,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),tDCS,Adults (>=18yo),Acceptability,Endpoint (~12wk),,Very low,RR,0.343,"[0.096, 1.217]",0.096,1.217,9.76e-02,"[0.021, 5.533]",3,103,3.15e-01,7.72e-01,no,100,100,-1.0700248318162,-2.3434070875143,0.19638881400539,Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),tDCS,Adults (>=18yo),Tolerability,Endpoint (~12wk),,Very low,RR,0.346,"[0.057, 2.078]",0.057,2.078,2.46e-01,"[0, 38841.235]",2,81,NaN,7.05e-01,no,100,100,-1.06131650392441,-2.86470401114759,0.731405892677036,Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
8996,Yin - adults (2024),tDCS,Adults (>=18yo),Exec. functions (tests),Endpoint (~12wk),N/A,Very low,G,0.303,"[0.003, 0.603]",0.003,0.603,4.78e-02,"[-0.355, 0.961]",3,156,5.95e-01,8.00e-01,no,100,51.7043840220641,0.303,0.003,0.603,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),TMS-rTMS,Adults (>=18yo),Acceptability,Endpoint (~12wk),,Very low,RR,0.614,"[0.301, 1.252]",0.301,1.252,1.79e-01,"[0.193, 1.952]",4,141,6.87e-01,7.45e-01,no,88.2370845645783,88.2370845645783,-0.487760350834995,-1.20064501423326,0.224742272677907,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),TMS-rTMS,Adults (>=18yo),Core ADHD symptoms [Self-rated],Endpoint (~12wk),Self-rated,Very low,G,0.025,"[-0.497, 0.547]",-0.497,0.547,9.26e-01,"[-1.44, 1.49]",4,118,4.19e-01,1.46e-01,no,75.8443911522927,75.8443911522927,0.025,-0.497,0.547,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)
999,Ostinelli (2025),TMS-rTMS,Adults (>=18yo),Tolerability,Endpoint (~12wk),,Very low,RR,1.065,"[0.261, 4.347]",0.261,4.347,9.31e-01,"[0.048, 23.366]",3,115,4.70e-02,6.15e-01,no,86.6414724163879,86.6414724163879,0.0629747991613884,-1.34323487165944,1.46948595200666,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
8997,Yu (2024),Viloxazine,Children/Adolescents (6-17yo),AE (sleep problems),Endpoint (~12wk),,Moderate,RR,0.266,"[0.155, 0.458]",0.155,0.458,1.81e-06,"[0.116, 0.613]",5,990,4.89e-02,3.73e-01,no,100,100,-1.32425897020044,-1.86433016206289,-0.780886094867952,Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)
8997,Yu (2024),Viloxazine,Children/Adolescents (6-17yo),Core ADHD symptoms [Mixed],Endpoint (~12wk),Mixed,Moderate,G,0.375,"[0.255, 0.495]",0.255,0.495,9.39e-10,"[0.205, 0.545]",5,990,8.96e-02,3.24e-01,no,100,100,0.375,0.255,0.495,Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)
8997,Yu (2024),Viloxazine,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Low,RR,0.764,"[0.541, 1.078]",0.541,1.078,1.25e-01,"[0.357, 1.633]",5,990,3.01e-02,3.63e-01,no,100,100,-0.269187489815617,-0.614336000135656,0.0751074724868055,Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
8997,Yu (2024),Viloxazine,Children/Adolescents (6-17yo),AE (decreased appetite),Endpoint (~12wk),,Very low,RR,0.18,"[0.055, 0.584]",0.055,0.584,4.31e-03,"[0.014, 2.389]",3,606,1.94e-02,2.17e-02,no,100,100,-1.71479842809193,-2.90042209374967,-0.53785429615391,Yu (2024)_Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)
8997,Yu (2024),Viloxazine,Children/Adolescents (6-17yo),Tolerability,Endpoint (~12wk),,Very low,RR,0.43,"[0.185, 0.999]",0.185,0.999,4.98e-02,"[0.13, 1.42]",5,990,4.79e-02,8.16e-01,no,100,100,-0.843970070294529,-1.68739945390381,-0.00100050033358353,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
1255,Gan (2019),Vitamin D,Children/Adolescents (6-17yo),Core ADHD symptoms [Mixed],Endpoint (~12wk),Mixed,Very low,G,0.42,"[-0.21, 1.05]",-0.21,1.05,1.91e-01,"[-5.9, 6.74]",2,125,NaN,4.61e-01,no,100,100,0.42,-0.21,1.05,Gan (2019)_Vitamin D_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)
1255,Gan (2019),Vitamin D,Children/Adolescents (6-17yo),Oppositional symptoms (ODD),Endpoint (~12wk),N/A,Very low,G,0.953,"[-0.223, 2.128]",-0.223,2.128,1.12e-01,"[-11.573, 13.478]",2,89,NaN,6.45e-01,no,100,100,0.953,-0.223,2.128,Gan (2019)_Vitamin D_Oppositional Defiant Disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)
575,Catala-Lopez (2017),Zinc,Children/Adolescents (6-17yo),Tolerability,Endpoint (~12wk),,Very low,RR,0.696,"[0.393, 1.233]",0.393,1.233,2.15e-01,"[0.017, 28.289]",2,456,NaN,7.13e-01,no,100,100,-0.362405618647717,-0.933945667112876,0.209450224182207,Catala-Lopez (2017)_Zinc_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)
575,Catala-Lopez (2017),Zinc,Children/Adolescents (6-17yo),Acceptability,Endpoint (~12wk),,Very low,RR,0.964,"[0.8, 1.162]",0.8,1.162,7.00e-01,"[0.712, 1.306]",4,536,2.91e-01,6.48e-01,no,99.2629403583229,99.2629403583229,-0.0366639843715915,-0.22314355131421,0.150142658429719,Catala-Lopez (2017)_Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)
3490,Talebi (2021),Zinc,Children/Adolescents (6-17yo),Core ADHD symptoms [Mixed],Endpoint (~12wk),Mixed,Very low,G,0.623,"[0.066, 1.179]",0.066,1.179,2.83e-02,"[-1.192, 2.437]",6,489,2.28e-01,8.74e-01,no,51.2320964730747,34.8386453443001,0.623,0.066,1.179,Talebi (2021)_Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)
